Ten investors actively back Melbourne healthtech startups in 2026. They range from biotech specialists to impact VCs and private equity firms. Here's who writes cheques, what they back, and how to reach them.
Melbourne is Australia's healthtech capital. Monash University, the Walter and Eliza Hall Institute, and CSIRO give Melbourne a research base that no other city matches.
Investors here split between biotech specialists who understand clinical pathways and digital health funds looking for B2B SaaS revenue.
The fundraising path for a biotech company looks different from a digital health startup. Biotech founders need longer runways and specialist investors. Digital health founders can target generalist VCs with health portfolios.
This guide covers ten Melbourne healthtech investors and the fastest way to approach each one.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Brandon Capital | Biotech VC | A$1M-A$15M | Biotech, healthtech | brandoncapital.com.au |
| OneVentures | Independent VC | A$500K-A$10M | Health, biotech, AI | oneventures.com.au |
| Main Sequence Ventures | Corporate VC (CSIRO) | A$500K-A$10M | Health AI, biotech | mainsequence.vc |
| Blackbird Ventures | Independent VC | A$200K-A$50M | Health AI, digital health | blackbird.vc |
| AirTree Ventures | Independent VC | A$100K-A$30M | Digital health, B2B | airtree.vc |
| Artesian VC | Multi-strategy VC | A$500K-A$10M | Health AI, impact tech | artesianvc.com |
| Skalata Ventures | Accelerator/VC | A$200K-A$2M | Healthtech, tech | skalata.co |
| OIF Ventures | Independent VC | A$1M-A$10M | Digital health, SaaS | oifventures.com |
| Giant Leap Fund | Impact VC | A$500K-A$5M | Health, impact, social | giantleap.com.au |
| Gresham Private Equity | Private equity | A$5M-A$50M | Health services, aged care | gresham.com.au |
Share your healthtech pitch deck securely
Ellty gives you trackable data room links that work for sensitive clinical documents.
Start free 14-day trialWhat healthtech VCs look for
Healthtech investors in Melbourne check two things first: regulatory pathway and reimbursement model. A product without a clear TGA or FDA pathway is hard to fund at any stage.
For digital health, they want enterprise SaaS contracts with hospitals or insurers - not consumer downloads. B2B health revenue is more predictable and easier to scale.
Biotech investors run extended due diligence on IP and clinical trial data. Make sure your virtual data room has patent filings, preclinical data, and CMC documentation ready before first meetings.
Impact VCs like Giant Leap add a second lens: social benefit metrics. Show patient outcomes and equitable access alongside commercial metrics.
Melbourne has the deepest pipeline of translational health research in the southern hemisphere. The challenge isn't finding great science - it's connecting it to the right commercial team.
10 Melbourne healthtech investors
1. Brandon Capital Partners
Australia's only specialist biotech VC managing MRCF funds backed by universities and research institutes.
Recent Deals: MRCF Fund VI actively deploying 2025-2026; clinical-stage biotech portfolio spanning oncology and immunology
LinkedIn: Brandon Capital Partners LinkedIn
Sector Focus: Biotech, medtech, life sciences
Stage Focus: Seed, Series A, Series B
Location: Melbourne, Australia
Website: brandoncapital.com.au
2. OneVentures
Michelle Deaker's fund - data-led thesis with a strong track record in health, biotech, and enterprise AI.
Recent Deals: Zepto A$25M Series A (2025) - instant payments; health AI and biotech investments ongoing through Fund IV
LinkedIn: OneVentures LinkedIn
Sector Focus: Health, biotech, AI
Stage Focus: Seed, Series A, Series B
Location: Melbourne, Australia
Website: oneventures.com.au
3. Main Sequence Ventures
CSIRO's VC - the only fund that brings direct research infrastructure alongside the cheque.
Recent Deals: Presagen Series B (2025) - AI for IVF; Nutromics seed - biosensor wearables; health AI portfolio active
LinkedIn: Main Sequence Ventures LinkedIn
Sector Focus: Health AI, biotech, deep tech
Stage Focus: Seed, Series A
Location: Melbourne, Australia
Website: mseq.vc
4. Blackbird Ventures
Backs founders building global category leaders - they take bets other Australian funds won't.
Recent Deals: Airwallex US$300M Series F (2025); Wild Futures programme backing health AI founders in Melbourne
LinkedIn: Blackbird Ventures LinkedIn
Sector Focus: Health AI, digital health, B2B
Stage Focus: Seed to growth
Location: Sydney, Australia
Website: blackbird.vc
5. AirTree Ventures
Australia's largest early-stage fund by AUM - A$2B across five funds, seed to Series B.
Recent Deals: A$650M Fund V closed 2025; Coviu telehealth follow-on; digital health portfolio growing
LinkedIn: AirTree Ventures LinkedIn
Sector Focus: Digital health, B2B SaaS
Stage Focus: Seed, Series A, Series B
Location: Sydney, Australia
Website: airtree.vc
6. Artesian VC
Broadest mandate in this list - health AI to aged care tech to impact, if the team is right.
Recent Deals: 5 investments past 12 months across health AI, diagnostics, and impact tech
LinkedIn: Artesian VC LinkedIn
Sector Focus: Health AI, impact tech, diagnostics
Stage Focus: Seed, Series A
Location: Melbourne, Australia
Website: artesianinvest.com
Know who's reading your healthtech pitch
Ellty data rooms track every investor interaction with your documents in real time.
Start free 14-day trial7. Skalata Ventures
Best entry point pre-revenue - 6-month accelerator with capital and structured mentorship.
Recent Deals: Paperly A$3M seed (Nov 2025); cohort 8 includes healthtech startups from Melbourne
LinkedIn: Skalata Ventures LinkedIn
Sector Focus: Healthtech, digital health, SaaS
Stage Focus: Pre-seed, seed
Location: Melbourne, Australia
Website: skalata.co
8. OIF Ventures
Don't pitch if you're still searching for PMF - they require concept validation upfront.
Recent Deals: Omniscient A$36M (May 2026) - healthcare AI platform; Starboard Maritime A$13.8M Series A co-invested
LinkedIn: OIF Ventures LinkedIn
Sector Focus: Digital health, B2B SaaS, AI
Stage Focus: Seed, Pre-Series A, Series A
Location: Sydney, Australia
Website: oifventures.com.au
9. Giant Leap Fund
Requires genuine measurable social outcomes - not sustainability language, actual patient metrics.
Recent Deals: Black Duck Consulting (2025) - Aboriginal workforce health; mental health and aged care portfolio active
LinkedIn: Giant Leap Fund LinkedIn
Sector Focus: Health impact, aged care, mental health
Stage Focus: Seed, Series A
Location: Melbourne, Australia
Website: giantleap.com.au
10. Gresham Private Equity
PE firm for health service businesses with A$5M+ revenue - they buy and scale, not seed.
Recent Deals: Growth equity in health services businesses ongoing 2025-2026; allied health and aged care focus
LinkedIn: Gresham Private Equity LinkedIn
Sector Focus: Health services, aged care, private hospitals
Stage Focus: Growth, buyout
Location: Melbourne, Australia
Website: gresham.com.au
Biotech vs digital health investors
Biotech investors in Melbourne require clinical evidence and regulatory expertise. They run longer due diligence cycles and expect 7-10 year investment horizons.
Digital health VCs move faster and focus on recurring revenue and enterprise contracts. A digital health company with A$1M ARR can close a Series A in 3-4 months.
Use granular permissions in your data room to control what each investor type sees. Biotech investors need clinical data that digital health VCs don't care about.
Run both tracks in parallel if your product has both a software and device component. Hybrid companies can target both pools of capital.
How to raise for a healthtech startup
Start with specialist funds before approaching generalist VCs. Brandon Capital and OneVentures understand clinical pathways. Most generalist VCs don't.
Your fundraising process should start with your data room ready, not after your first meeting. Healthtech investors ask for clinical data within 48 hours of a positive first call.
Mergers and acquisitions are common exits for Melbourne healthtech. Show investors your M&A landscape alongside your IPO path - acquirer interest signals commercial validation.
Keep your monthly investor updates to one page with three metrics: clinical milestones, ARR, and runway. Ellty's analytics show you who's reading each update so you know where to invest follow-up time.
Preparing for healthtech due diligence
Healthtech due diligence is more extensive than most sectors. Investors check TGA regulatory status, clinical trial protocols, and reimbursement strategy in parallel.
Financial diligence for healthtech includes grant funding, R&D tax offset claims, and milestone-based revenue. Read our financial due diligence guide to structure your financials correctly.
Operational due diligence covers your manufacturing partners, clinical trial sites, and regulatory affairs team. Our operational due diligence guide shows what investors verify.
AI-powered health products face additional scrutiny. Investors check model bias, data consent, and clinical validation separately. Read our AI due diligence guide to prepare.
Why smart money is pouring into Australian biotech in 2026
How to pitch a Melbourne healthtech investor
Prepare your clinical and commercial case before your first investor meeting.
- 1.Know your regulatory pathway firstLead with your TGA or FDA status. Investors kill deals when the regulatory path is unclear.
- 2.Target the right investor typeBiotech needs specialist VCs. Digital health can pitch generalists. Don't mix these up.
- 3.Have clinical evidence readyInvestors ask for preclinical or clinical data within days of first contact. Prepare it now.
- 4.Send your data room immediatelyShare your Ellty data room after the first call. Track who reviews clinical vs commercial docs.
- 5.Follow up with one milestoneReport a trial result, a new hospital contract, or a TGA milestone. Keep follow-ups specific.
How Ellty helps you land a healthtech investor in Melbourne
Ellty is a data room for healthtech founders. Keep clinical and commercial documents in separate, controlled folders.
- 1.Organise clinical and commercial docsCreate separate folders for clinical data and investor materials. Set permissions per investor tier.
- 2.Share trackable linksSend each investor a unique link. Ellty logs every open and time spent on each document.
- 3.Know who's engagedSee which investors reviewed your clinical data. Follow up the same day they go deep on your docs.
Melbourne healthtech investors: common questions
- They check regulatory pathway, reimbursement model, and clinical evidence first. Revenue and team come second.
- Biotech for drug and device companies. Generalist VCs for digital health with recurring revenue. Know the difference.
- Digital health can close in 3-5 months. Biotech rounds take 6-12 months due to clinical due diligence.
- The MRCF is managed by Brandon Capital and backed by Australian universities. Apply through Brandon Capital.
- Deck, financials, regulatory filings, clinical trial protocols, and IP documentation. Have all of these ready.
